# US 8,465,936 B2 · Method for determining the sensitivity of patients suffering from a cancer disease to biological therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,465,936 B2
- Document ID: US8465936B2
- Status: Granted
- Kind: B2
- Application number: 12/863,517
- Filed: 2009-01-23
- Published: 2011-01-20
- Granted: 2013-06-18
- Earliest claimed: 2008-01-25
- Assignees: Univerzita Palackeho V Olomouci, Lekarska Fakulta; Masarykuv Onkologicky Ustav
- Applicants: Marian Hajduch; Marta Dziechciarkova; Lenka Radova; Marek Svoboda
- Inventors: Marian Hajduch; Marta Dziechciarkova; Lenka Radova; Marek Svoboda
- Web page: https://patentgrep.com/patent/US8465936B2

## CPC

- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- G01N 2333/912: transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention relates to a method for determining the sensitivity of patients suffering from a cancer disease towards targeted biological therapy based on the inhibition of signaling pathways of the members of HER family (e.g., HER-1, HER-2, HER-3 and HER-4) by determining the expression of the biomarker S6 kinase or its post-translationally modified form or of the biomarkers of the activation of S6 kinase or their post-translationally modified forms in the tumor.

## Claims

### Claim 1

A method for determining the sensitivity of a breast cancer patient to trastuzumab therapy comprising:
(a) obtaining a breast tumor tissue sample;
(b) measuring the level of S6Kinase 1 (S6K1) protein or the level of S6K1 phosphorylation at Serine235/236 in the sample; and
(c) identifying the patient as sensitive to trastuzumab therapy when the sample is negative for S6K1 protein expression or phosphorylation at Serine235/236, and
identifying the patient as resistant to trastuzumab therapy when the sample is positive for S6K1 protein expression or phosphorylation at Serine235/236.